Market
What will be the main barrier to Lenacapavir's adoption by end of 2025?
2
Resolution / Starting Odds
Cost • 25%
Regulatory approvals • 25%
Manufacturing capacity • 25%
Public awareness • 25%
Reports and studies from health organizations and market research firms
Story
Twice-Yearly Lenacapavir Injection Shows 95% Effectiveness, 96% Risk Reduction in HIV Prevention
Dec 1, 2024, 01:35 PM
A twice-yearly injectable HIV prophylactic, Lenacapavir, has shown over 95% effectiveness in preventing HIV infections in men, according to recent studies. The injection has also been proven effective in women and offers a significant advantage over daily pills like F/TDF due to better adherence rates. Another study highlighted that a semi-annual injection reduced the risk of HIV infection by 96%. Additionally, achieving an undetectable viral load through consistent antiretroviral therapy means zero risk of transmission. This development represents a promising step toward combating HIV/AIDS, although questions remain about equitable access to the treatment.
View original story
Similar markets
Distribution • 25%
Regulatory approval • 25%
Adherence • 25%
Cost • 25%
Regulatory hurdles • 25%
Logistical challenges • 25%
Other • 25%
Funding issues • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Hospitals • 25%
Community health programs • 25%
Pharmacies • 25%
Clinics • 25%
Not approved in USA or EU • 25%
Approved in USA only • 25%
Approved in EU only • 25%
Approved in both USA and EU • 25%
Global Fund • 25%
Other • 25%
Gilead Sciences • 25%
PEPFAR • 25%
Adults • 25%
Adolescents • 25%
Pregnant women • 25%
Elderly • 25%
